Search the Newsreel

Price to earnings forward of Qiniu Limited – HKEX:2567

Genius Sports (GENI) After Q2 Earnings And New Deals Looks Cheap By The Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Q2 earnings set the tone for Genius Sports stock Genius Sports (GENI) is back in focus after reporting Q2 2026 earnings that combined higher sales with a …

A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $50 to $75

This article provides a quick overview of analyst ratings for Definium Therapeutics (DFTX.US), highlighting a price target forecast ranging from $50 to $75. It emphasizes that these ratings can influence investor decisions and future stock performance for the company.

Uranium Royalty Appoints New Directors to the Board

Uranium Royalty Corp. (URC) has announced the appointment of Kevin McQuilkin and Peter Rozenauers to its Board of Directors, effective immediately. Both new directors bring extensive experience in finance, mining, and natural resources, which CEO Scott Melbye stated will be valuable as the company …

Fresenius Medical Care AG (FMS) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Uranium Royalty (TSX:URC) - Stock Analysis

This article provides a detailed stock analysis of Uranium Royalty (TSX:URC), highlighting its financial performance, growth prospects, and recent corporate developments. Key updates include new board appointments, a recent acquisition of Sweetwater Royalties LLC, and changes in price targets and insider transactions. The company's …

Genius Sports Q2 Earnings Call Highlights

Key Points Interested in Genius Sports Limited? Here are five stocks we like better. Strong Q2 performance: Genius Sports reported revenue of $196 million, up 65% year over year, and adjusted EBITDA of $53 million, exceeding its guidance. Growth was driven by betting, media, …

Fresenius Medical Care AG & Co. KGaA $FMS Position Boosted by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Fresenius Medical Care AG & Co. KGaA by 80.7%, now owning 120,704 shares. Other institutional investors like Morgan Stanley and Bank of America also boosted their positions, although overall institutional ownership remains at 8.37%. Despite beating …

Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Recommendation of "Buy" from Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has received a consensus "Buy" recommendation from eighteen analysts, with an average 12-month price target of $55.00. Despite analysts' bullish outlook and recent stock gains, the company missed its quarterly earnings estimates, reporting a loss of $1.44 per share against …

Definium Therapeutics (NASDAQ:DFTX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Definium Therapeutics (NASDAQ:DFTX) to a "Sell" rating, a move that contrasts with the majority "Buy" consensus among other analysts. This downgrade follows Definium Therapeutics missing its quarterly earnings estimates significantly, reporting a loss of $1.44 per share against an …

Is Genius Sports (GENI) Still Cheap As Strong Q2 Results And New Deals Lift Expectations?

Genius Sports (GENI) has seen its shares rebound following strong Q2 2026 results, increased full-year revenue guidance, and new prediction market partnerships. Despite a year-to-date decline, the company's valuation is being debated, with a popular narrative suggesting it's 26% undervalued at a fair value …

Needham raises Genius Sports stock price target on media growth

Needham has increased its price target for Genius Sports Ltd. (NYSE:GENI) to $12.00 from $10.00, maintaining a Buy rating due to strong media growth, new deals, and an impressive 42% revenue increase. The company surpassed Q2 revenue expectations, leading to a raised full-year outlook, …

Genius Sports (NYSE:GENI) Issues Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Why Genius Sports Popped by Almost 10% This Week

Fresenius Medical Care AG 2026 Q2 - Results - Earnings Call Presentation (NYSE:FMS) 2026-08-07

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 9:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Chair of the Management Board - Helen Giza Chief Financial Officer - Martin Fischer Investor Relations - Dominik Heger Full Conference Call Transcript Operator: …

Form 8K Uranium Royalty Corp. For: 7 August By Investing.com

This article reports on a Form 8K filing by Uranium Royalty Corp. for August 7th. It indicates that the document was published by Investing.com. The content itself provides no further details beyond the filing's date and the company's name.

Uranium Royalty adds two directors to board

Uranium Royalty Corp. (NASDAQ:UROY) has appointed Kevin McQuilkin and Peter Rozenauers to its board of directors. McQuilkin brings over 35 years of investment banking experience in energy, metals, mining, and chemicals, while Rozenauers has more than 35 years of experience in the natural resources …

Mega Uranium Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

NIU TECHNOLOGIES Q2 2026 Earnings Preview: Recent $NIU Insider Trading, Hedge Fund Activity, and More

NIU Technologies (NIU) is set to release its Q2 2026 earnings on August 10th, with analysts projecting revenues of $1.596 billion and earnings of $1.28 per share. Insider trading activity shows one sale by the CFO in the last six months. Hedge fund activity …

Ternium (TX) Q2 Margin Strength Lifts Interest, Is The Stock Fairly Valued?

Barclays Sticks to Its Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Barclays has maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X) with a price target of €44.50. This rating aligns with Goldman Sachs's Hold, while Jefferies reiterated a Sell rating on the company. Fresenius Medical Care currently has a market …

Niu Technologies (NIU) Options Chain

This article provides the options chain for Niu Technologies (NIU), detailing call and put options with various strike prices, last trade dates, prices, bids, asks, and implied volatility. It also includes the current stock price, after-hours trading data, and an announcement for the Q2 …

Definium Therapeutics (NASDAQ: DFTX) builds $1.1B cash war chest as Phase 3 data hit

Definium Therapeutics reported a Q2 2026 net loss of $158.986 million and a six-month net loss of $236.1 million, despite building a substantial cash reserve of $1.1 billion. This strong liquidity position, largely due to an $805 million equity offering in June 2026, is …

Tuniu Corp (TOUR) Stock News Today

Oppenheimer Forecasts Strong Price Appreciation for Genius Sports (NYSE:GENI) Stock

Genius Sports (NYSE:GENI) Earns "Equal Weight" Rating from Wells Fargo & Company

Wells Fargo & Company reaffirmed an "Equal Weight" rating for Genius Sports (NYSE:GENI) with an $8.00 price target. The company reported quarterly revenue of $195.5 million, exceeding estimates, but also a larger-than-expected loss of $0.28 per share. Despite the loss, analyst sentiment remains broadly …

Enterprise value to revenue forward of Uranium Royalty Corp. – NASDAQ:UROY

This article presents the enterprise value to revenue forward for Uranium Royalty Corp. (NASDAQ: UROY). It shows financial data for the company, accessible through TradingView, and indicates that the market was closed at the time of the data display. The content is primarily a …

Elevate Uranium Extends Deadline to Lift Marenica Project Stake to 90%

Fresenius Medical Care AG: Ergebnis verfehlt Analystenschätzungen: Das prognostizieren Analysten jetzt

Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Definium Therapeutics, Inc. Q2 2026: Net loss $(159.0)M, Diluted loss per share $(1.44) — 10-Q Summary

Definium Therapeutics, Inc. reported a significant increase in net loss for Q2 2026, reaching $(159.0)M compared to $(42.7)M in Q2 2025, with diluted loss per share rising to $(1.44). The company had no reported revenue but highlighted several clinical and regulatory advancements including fully …

Earnings call transcript: Definium Therapeutics posts wider Q2 2026 loss as stock rises

Definium Therapeutics reported a wider net loss of $159 million in Q2 2026, primarily due to an $86.2 million non-cash warrant revaluation charge, even as its stock rose. The company increased R&D and G&A expenses to support late-stage trials for its lead drug DT120 …

Tuniu Corp (TOUR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Tuniu Corp (TOUR), detailing its current earnings forecast score, average price target, and analyst ratings. Based on one analyst, the target price for TOUR is $1.70, suggesting a 148.25% upside. The stock is currently rated as a …

Earnings Flash (DFTX) Definium Therapeutics Posts Q2 EPS -$1.44, vs. FactSet Est of -$0.54

Definium Therapeutics (DFTX) reported a Q2 EPS of -$1.44, significantly missing the FactSet estimate of -$0.54. The company's Q2 loss widened, as announced on August 6, 2026, alongside their earnings call. Definium Therapeutics focuses on developing treatments for psychiatric and neurological disorders, with its …

Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge

Definium Therapeutics (NASDAQ:DFTX) reported a Q2 net loss of $1.44 per share, significantly missing the $0.56 consensus estimate, causing shares to fall by about 4.7% after-market. The large loss was primarily due to an $86.2 million non-cash charge from warrant liabilities, although operating losses …

BTIG Research Boosts Genius Sports (NYSE:GENI) Price Target to $10.00

BTIG Research has increased its price target for Genius Sports (NYSE:GENI) to $10.00 from $9.00, maintaining a "buy" rating and suggesting a 26.41% upside. This comes amidst broadly positive analyst sentiment, with an average price target of $11.19. Despite reporting strong quarterly revenue growth …